As part of your daily routine as an active trader or investor, it's important to track the stocks in the market that are making the biggest percentage gains and the biggest percentage losses.

Stocks that are making large moves to the upside are favorites among short-term traders who want to capture some of that massive volatility. Stocks that are making big-percentage moves are usually in play because their sector is becoming attractive or they have a major fundamental catalyst such as a recent earnings release. Sometimes stocks making big moves have been hit with an analyst upgrade or an analyst downgrade.

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits. If you time your trade correctly, combining with fundamental trends, discipline and sound money management, you will be well on your way to investment success.

With that in mind, let's take a closer look at a several stocks under $10 that are making large moves to the upside.

Marinus Pharmaceuticals

  • Thursday's Range: $6.16-$6.82
  • 52-Week Range: $4.52-$20.72
  • Thursday's Volume: 113,000
  • Three-Month Average Volume: 134,080

Marinus Pharmaceuticals  (MRNS) , a clinical stage biopharmaceutical company, focuses on developing and commercializing neuropsychiatric therapeutics. This stock traded up 10.5% to $6.79 in Thursday's trading session.

From a technical perspective, Marinus Pharmaceuticals counter-trended higher on Thursday versus the overall market weakness right above some near-term support at $5.80 a share with decent upside volume flows. This spike to the upside also pushed shares of Marinus Pharmaceuticals back above its 20-day moving average of $6.43 a share, and it's quickly moving the stock within range of triggering a major breakout trade. That trade will trigger if this stock manages to take out its 50-day moving average of $7.10 a share and then above more near-term resistance at $7.39 a share with high volume.

Traders should now look for long-biased trades in Marinus Pharmaceuticals as long as it's trending above some key near-term support at $5.80 a share and then once it sustains a move or close above those breakout levels with volume that hits near or above 134,080 shares. If that breakout kicks off soon, then this stock will set up to re-fill some of its previous gap-down-day zone from November that started at $8.43 a share.

Ocular Therapeutix

  • Thursday's Range: $9.28-$9.95
  • 52-Week Range: $6.75-$44.19
  • Thursday's Volume: 291,000
  • Three-Month Average Volume: 311,733

Ocular Therapeutix  (OCUL) , a biopharmaceutical company, focuses on the development and commercialization of therapies for eye diseases and conditions using its proprietary hydrogel platform technology in the U.S. This stock traded up 4.6% to $9.68 in Thursday's trading session.

From a technical perspective, Ocular Therapeutix spiked sharply higher on Thursday and showed relative strength vs. the overall market weakness after the stock bounced off its 20-day moving average of $9.17 a share with decent upside volume flows. This trend to the upside is now quickly pushing shares of Ocular Therapeutix within range of triggering a major breakout trade above some key near-term overhead resistance levels. That trade will trigger if this stock manages to take out some key near-term overhead resistance levels at $10.15 to its 50-day moving average of $10.58 a share with high volume.

Traders should now look for long-biased trades in Ocular Therapeutix as long as it's trending above its 20-day moving average of $9.17 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 311,733 shares. If that breakout takes hold soon, then this stock will set up to re-test or possibly take out is next major overhead resistance levels at $11 to its gap-down-day high from October at around $12 a share. Any high-volume move above $12 will then give this stock a chance to re-fill its previous gap-down-day zone that started near $16 a share.

Rosetta Genomics

  • Thursday's Range: $1.18-$1.25
  • 52-Week Range: $1.05-$5.55
  • Thursday's Volume: 176,000
  • Three-Month Average Volume: 247,338

Rosetta Genomics  (ROSG)  develops and commercializes microRNA-based diagnostic tests and therapeutics. This stock traded up 4.2% to $1.24 in Thursday's trading session.

From a technical perspective, Rosetta Genomics spiked notably higher on Thursday right above some near-term support levels just below $1.20 a share with lighter-than-average volume. This stock recently formed a double bottom chart pattern, after shares found some buying interest at $1.15 to $1.16 a share. Following that bottom, shares of Rosetta Genomics have now started to spike higher, and it's quickly moving within range of triggering a near-term breakout trade. That trade will trigger if this stock manages to take out some key near-term overhead resistance levels at $1.29 to $1.31 a share and then once it clears its 20-day moving average of $1.32 to more resistance near $1.40 a share with high volume.

Traders should now look for long-biased trades in Rosetta Genomics as long as it's trending above those recent double bottom support levels and then once it sustains a move or close above those breakout levels with volume that registers near or above 247,338 shares. If that breakout fires off soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels near $1.60 to $1.80 a share.

Argos Therapeutics

  • Thursday's Range: $1.65-$1.87
  • 52-Week Range: $1.61-$10.56
  • Thursday's Volume: 97,000
  • Three-Month Average Volume: 29,634

Argos Therapeutics  (ARGS) , a biopharmaceutical company, focuses on the development and commercialization of personalized immunotherapies for the treatment of cancer and infectious diseases in North America. This stock traded up 9.4% to $1.85 in Thursday's trading session.

From a technical perspective, Argos Therapeutics spiked sharply higher on Thursday right above its new 52-week low of $1.61 a share with above-average volume. This stock has been downtrending badly over the last two months and change, with shares collapsing off its high of $6.35 to its new 52-week low of $1.61 a share. During that downtrend, shares of Argos Therapeutics have been consistently making lower highs and lower lows, which is bearish technical price action. That said, this stock has now started to rebound off that $1.61 low and it's now quickly moving within range of triggering a near-term breakout trade. That breakout will trigger if this stock manages to take out Thursday's intraday high of $1.87 a share to some more key resistance levels at $2 to around $2.15 a share with high volume.

Traders should now look for long-biased trades in Argos Therapeutics as long as it's trending above its new 52-week low of $1.61 a share and then once it sustains a move or close above those breakout levels with volume that registers near or above 29,634 shares. If that breakout develops soon, then this stock will set up to re-test or possibly take out its next major overhead resistance levels at $2.50 to $3, or even its 20-day moving average of $3.21 a share.

Disclosure: This article is commentary by an independent contributor. At the time of publication, the author held no positions in the stocks mentioned.

More from Opinion

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Attention 60 Minutes: Google Isn't the Only Big-Tech Monopoly

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Apple Buys Tesla? Amazon Buys Sears? 3 Dream Mergers That Just Make Sense

Amazon's Assault on Grocery Stores Will Have a Profound Impact on Many

Amazon's Assault on Grocery Stores Will Have a Profound Impact on Many

It's Dumb to Think There Aren't Already Monopolies in Big Tech

It's Dumb to Think There Aren't Already Monopolies in Big Tech

Google's EU Battles Are Hardly a Reason to Panic

Google's EU Battles Are Hardly a Reason to Panic